CJC-1295 (no DAC) is a synthetic peptide that is a modified form of growth hormone-releasing hormone (GHRH), specifically designed to stimulate the release of growth hormone (GH) from the pituitary gland. Unlike its precursor, GHRH, CJC-1295 (no DAC) does not include the drug affinity complex (DAC) group, which means it has a shorter half-life and requires more frequent administration. This makes it suitable for research settings where controlled, periodic dosing is necessary to study its effects on growth hormone secretion and overall physiological impact.

CJC-1295 (no DAC) is often utilized in clinical and research environments to explore the potential benefits of enhanced growth hormone levels. Growth hormone plays a crucial role in a variety of bodily functions, including the promotion of muscle growth, fat metabolism, and tissue repair. By mimicking natural GHRH, CJC-1295 (no DAC) stimulates the pituitary gland to secrete growth hormone in a pulsatile manner, leading to the release of both GH and insulin-like growth factor 1 (IGF-1), which is instrumental in muscle repair and growth.

Research has shown that the use of CJC-1295 (no DAC) can support various benefits, especially in individuals who experience growth hormone deficiencies, such as aging adults or those with specific metabolic conditions. It has demonstrated potential in improving body composition by promoting fat loss and increasing lean muscle mass, making it a valuable peptide for studies on obesity, muscle wasting, and related disorders. The peptide also has regenerative properties, supporting the repair and regeneration of damaged tissues, including muscle and skin, which has led to its exploration for potential anti-aging applications.

CJC-1295 (no DAC) is typically used in combination with other peptides in research on human health, including weight management and physical performance enhancement. Its potential to improve athletic performance and recovery times has also been investigated, as it stimulates muscle growth and repair processes by increasing GH and IGF-1 production.

While CJC-1295 (no DAC) has shown promising results in clinical trials, it should only be used under the guidance of qualified researchers and healthcare professionals. The peptide's mechanism of action, involving growth hormone release stimulation, makes it an important tool in understanding the complex processes of muscle building, fat metabolism, and regenerative tissue repair. Further studies continue to explore its safety, efficacy, and potential applications in various medical conditions.

Type: Synthetic peptide
Amino Acid Sequence:
Tyr-D-Ala-Gly-Ser-Pro-Asn-Glu-Thr-Tyr-Gln-Ala-Ser-Pro-Ser-Pro-Glu-Ala-Ser-Tyr-Leu-Tyr
Form:
CJC-1295 (no DAC) is commonly found in lyophilized powder form, intended for reconstitution with bacteriostatic water or saline solution. It is generally packaged in vials for reconstitution and injectable use.
How It Works:
CJC-1295 (no DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone (GH) in a pulsatile manner, which in turn increases the secretion of insulin-like growth factor 1 (IGF-1), leading to increased muscle growth, fat breakdown, and tissue repair.

Potential Benefits:

• Muscle Growth & Repair: Stimulates GH release, which enhances muscle growth and recovery (strong).
• Fat Loss: Encourages fat breakdown and enhances fat metabolism (moderate).
• Improved Recovery & Regeneration: Promotes tissue repair and regeneration, aiding in faster recovery from injuries (moderate).
• Anti-Aging Effects: Supports skin regeneration and overall vitality by boosting GH and IGF-1 levels (moderate).
• Enhanced Performance: Supports increased energy levels, strength, and physical performance (moderate).

Common Research Uses:

• Growth Hormone Deficiency: Researchers use CJC-1295 (no DAC) to study its potential for addressing growth hormone deficiencies in aging individuals or those with metabolic disorders (Primary).
• Body Composition: It is often explored for its effects on fat loss and muscle mass preservation in research focused on obesity and muscle wasting (Primary).
• Recovery & Regeneration: Used to study tissue repair and regeneration, including its impact on recovery from injuries or surgeries (Secondary).
• Athletic Performance: Investigated for its potential to improve strength, endurance, and overall athletic performance (Secondary).
• Anti-Aging Research: Studied for its potential anti-aging benefits, particularly related to skin elasticity and overall vitality (Indirect).

Administration:
CJC-1295 (no DAC) is most commonly administered via subcutaneous (SQ) injection, although it can also be administered intramuscularly (IM). The most effective and bioavailable method is SQ injection. Typically, the peptide is injected into the abdomen or thigh. In clinical research, it is often administered 2-3 times per week, depending on the study design and dosage requirements. Other methods like oral or intranasal administration are not common due to bioavailability limitations.

Dosage:

• Typical dosing range: The common dosing range is between 0.5 mg to 2 mg per week, typically split into two to three injections.
• Starting Dose: The most common starting dose for humans in research is 0.5 mg to 1 mg per week, with gradual increases based on response and tolerance.
• Titration schedule: Increases can be made by 0.5 mg per week as necessary, depending on desired effects and clinical response.
• Maximum Safe Dose: Clinical studies suggest that up to 2 mg per week is generally well-tolerated and safe for most individuals, although higher doses may be studied in certain contexts.
• Cycling recommendations: Researchers often recommend using CJC-1295 (no DAC) in cycles of 6-12 weeks with breaks in between to avoid receptor desensitization.

Safety Profile:
CJC-1295 (no DAC) has demonstrated a relatively safe profile in clinical trials with few reported adverse effects. It is generally well-tolerated, but side effects can occur in some individuals.

• Potential Side Effects:
• Safety Summary: Most side effects are mild and short-lived, with adverse reactions typically occurring when dosages are too high or rapid titration is used. Proper administration techniques and gradual dose increases help mitigate risks.
• Precautions/Interactions: Care should be taken with other peptides or drugs that alter hormone levels, as they may interfere with CJC-1295's mechanism of action. Those with a history of pituitary tumors or growth-related conditions should use this peptide under strict supervision.